View More Recent Stories
-
Cigna Corp. (CI) Tops Q3 EPS by 28c; offers guidance
-
Cigna Corp. (CI) call put ratio 11.3 calls to 1 put into quarter results
-
Deutsche Bank Reiterates Hold Rating on Humana (HUM)
-
Cigna Corp. (CI) options active on 4K contracts
-
Centene (CNC) on watch on vague chatter
-
Cigna Corp. (CI) Is Said To Resume Merger Discussions With Humana (HUM) - Bloomberg
-
Attorney General Ken Paxton Sues Big Pharma Drug Manufacturers and Pharmacy Benefit Managers for Conspiracy That Increased Insulin Prices by 1,000%
-
Humana (HUM) Sinks After Issuing Update on Medicare Advantage Plans for 2025
-
Bernstein SocGen Group Reiterates Outperform Rating on CIGNA (CI)
-
Bernstein SocGen Group Reiterates Outperform Rating on CIGNA (CI)
-
Cigna Corp. (CI): Express Scripts Comments on FTC's Reckless Insulin Action
-
FTC Sues Prescription Drug Middlemen for Artificially Inflating Insulin Drug Prices
-
Cigna's (CI) Express Scripts Sues FTC, Demands Withdrawal of PBM Report
-
CIGNA (CI) PT Raised to $422 at Jefferies
-
Cigna Corp. (CI) Tops Q2 EPS by 29c; offers guidance
-
FTC to Sue Drug Managers over Insulin Prices - WSJ
-
Piper Sandler Starts CIGNA (CI) at Overweight
-
Medicare Advantage Plans Quality Ratings To Be Recalculated - WSJ

